← Back to Clinical Trials
Recruiting Phase 4 NCT03781752
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
Condition ADHD
Sponsor Icahn School of Medicine at Mount Sinai
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 500
Sex ALL
Min Age 6 Years
Max Age 17 Years
Start Date 2018-03-04
Completion 2025-08
All Conditions
Interventions
Methylphenidate
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Eligibility Criteria
Inclusion Criteria: \- Youth ages 6-17 years with ADHD as a primary diagnosis Exclusion Criteria: * Participants that do not have ADHD as a primary diagnosis * Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians * Participants that are smokers or, are pregnant
Related Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology